- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05658757
Preliminary Effect of Food Processing and Sweeteners on Glycemic and Metabolic Measures
A Randomized Crossover Pilot Study Investigating the Impact of a "Natural" Low-Calorie Sweetener (Allulose) on Glycemic and Metabolic Measures
Study Overview
Status
Conditions
Detailed Description
The average adult in the United States consumes around 17 teaspoons a day of added sugar, or nearly 280 calories, far exceeding recommended levels; and the leading sources of added sugars in the US diet are sugar-sweetened beverages, desserts and sweet snacks, candy, additions to coffee and teas, and substantial but insidious levels in foods such as brefakfast cereals. Indeed, this is fueled by intake of ultra-processed foods, which provide 58 % of energy intake and 89 % of added sugars in the American diet. A significant body of evidence links high intake of added sugars to the spectrum of chronic diseases which predominate the current, era, particularly those impacted by glycemia, and particularly postprandial glycemia, which has a clear role in health and disease. Thus, it is no surprise that a leading health indicator for Healthy People 2030 is to "reduce consumption of added sugars by people aged 2 years and over". Despite myriad efforts to reduce sugar-sweetened beverage intake (which has occurred on some levels), levels of added sugars have continued to increase over the past decade. A major bottleneck in addressing the goal of reducing added sugars in the American diet has been the lack of products lower in added sugars or sugar-free that the average adult in the US finds palatable and doesn't carry ingrained stigma or taste preferences which limit intake (i.e., sweetened by FDA approved artificial sweeteners). Very recently, a potential solution to this bottleneck has appeared in the form of allulose, a natural "zero calorie" sweetener found in small amounts of maple syrup, dried fruits, and brown sugar. This sweetener is intended to be incorporated into bakery products, beverages, confectionaries, dairy products and as a straight sugar substitute. Additionally, there is preliminary evidence from basic science, and small trials in humans that shows benefit of intake in place of regular added sugar in both healthy populations and in individuals with type 2 diabetes in respect to glycemic dynamics. Thus, there is a need to begin testing whether intake of commercial products sweetened with allulose can indeed be an approach to reduce added sugar intake and improve glycemia, particularly in people with metabolic abnormalities who are more sensitive to added sugar intake.
Therefore, the investigators are proposing the following specific aims for this pilot study.
Aim 1: To inform hypotheses and test the preliminary effectiveness of the ability of commercial products sweetened with allulose to reduce added sugar intake and reduce measures of glycemia, the investigators will carry out a randomized crossover dietary intervention with provision of categories of participant chosen food with specific consumption instructions, that compares a period of intake of regular sweetened commercial foods (processed and high added sugar), a period of intake of allulose sweetened commercial products (processed and low added sugar), and a period emphasizing whole and minimally processed and sweetened foods (low processed and low added sugar).
Aim 2: The investigators will measure dietary intake to estimate diet quality in each period, as well as measure blood pressure, weight, and psychosocial measures to provide a comprehensive initial impact of these approaches, and inform hypotheses for longer and more comprehensive future research.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Irvine, California, United States, 92697
- University of California, Irvine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- type 2 diabetes with HbA1c < 8.5%, or prediabetes (defined by HbA1c of 5.7-6.4%) or fasting glucose (≥ 100 mg/dl )
- or abdominal obesity (defined by sex and ethnic based thresholds: Europid/Sub-Saharan Africa/E Med-Middle E ethnicity (M 94 cm / F 90 cm), S/SE/E Asian and ethnic S and Central Americans (M 90 cm / F 80 cm) with at least one other abnormality from the following: (elevated triglycerides (≥ 150 mg/dl), elevated LDL (≥ 130 mg/dl or Rx), low HDL (<40 mg/dl M, <50 mg/dl F, or Rx), elevated blood pressure (>130 systolic or > 85 diastolic, or Rx).
- Free of clinically significant or unstable pulmonary, cardiovascular, gastrointestinal, hepatic, or renal functional abnormality; or currently pregnant.
- Weight stable for past 3 months (+- 5% of current body weight) and not planning to lose or gain weight over study period.
- able to provide informed consent
- otherwise healthy (beyond above noted health criteria), who meet the following criteria: interested in participating in and adhering to the prescribed 6-week long study comprised of 3, 2-week periods
- access to a telephone
- a stable dietary history, defined as neither introducing nor eliminating a major food group in their diet for at least the previous month
- eat a breakfast meal or morning snack (defined as an eating occasion after waking and before eating a lunch meal) 5 or more times a week on average
- 2 servings a day of food/beverage with > 20% of added sugar intake for day (10 g/serving) as estimated from dietary and beverage survey
Exclusion Criteria:
- Never diagnosed with Alzheimer's disease or related dementias, or any cognitive related conditions (interfere with ability to participate and respond to outcome assessments)
- Currently pregnant (self-report) or planning to become pregnant during study period, -Current participation in another interventional clinical trial
- Previous randomization in the study
- Current treatment for cancer
- Systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg
- Major surgery planned during study duration
- Any disease or health condition which requires adherence to a specific diet/eating pattern that would prohibit participation
- Food insecurity assessed by Six-Item Short Form of the Food Security Survey Module (score > 1)
- Not responsible for choice of > 50% of dietary intake,
- work or obligations that require being awake during 3rd or overnight shift
- > 14 alcohol drinks /week
- heavy marijuana/THC product usage (> 5 days / week)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Regular sweetened commercial foods (processed and high added sugar)
This is the "usual" habits period. Participants consume the chosen, sweetened commercial products of their choice in the breakfast cereal/cereal-granola bar category (at least 1 daily serving) and sweetened baked goods/candy/desserts (at least 1 daily serving).
|
This is your "usual" habits period. Consume the chosen, sweetened commercial products of your choice in the breakfast cereal/cereal-granola bar category (at least 1 daily serving) and sweetened baked goods/candy/desserts (at least 1 daily serving).
Other Names:
|
|
Experimental: Allulose sweetened commercial foods (processed and low added sugar)
This period emphasizes minimizing added sugar, aligning intake levels with recommendations from the AHA and Dietary guidelines by consuming allulose sweetened products. Participants will eat at least 1 daily serving of the chosen, provided allulose sweetened breakfast/cereal-granola bar, and at least 1 daily serving of allulose sweetened baked goods/candy/desserts in place of the usual sweetened products from these food categories.
|
This period emphasizes minimizing added sugar, aligning intake levels with recommendations from the AHA and Dietary guidelines by consuming allulose sweetened products. Participants will eat at least 1 daily serving of the chosen, provided allulose sweetened breakfast/cereal-granola bar, and at least 1 daily serving of allulose sweetened baked goods/candy/desserts in place of the usual sweetened products from these food categories.
Other Names:
|
|
Experimental: Whole and minimally processed and sweetened foods (low processed and low added sugar)
This period emphasizes incorporating minimally processed (e.g., intact whole grains) foods with minimal to no added sugar, aligning added sugar intake levels with recommendations from the American Heart Association and Dietary guidelines. Consume at least 1 daily serving of the chosen, minimal to no sweetened breakfast food in place of "usual" sweetened breakfast cereal/cereal-granola bar and consume a whole piece of fruit (or serving of fruit) in place of a sweetened baked goods/candy/desserts (at least 1 daily serving).
|
Consume at least 1 daily serving of the chosen, minimal to no sweetened breakfast product in place of your "usual" sweetened breakfast cereal/cereal-granola bar and consume a whole piece of fruit (or serving of fruit) in place of a sweetened baked goods/candy/desserts (at least 1 daily serving).
This period emphasizes incorporating minimally processed (e.g., intact whole grains) foods with minimal to no added sugar, aligning added sugar intake levels with recommendations from the American Heart Association and Dietary guidelines.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycemic Variability (and specifically the Coefficient of Variation -CV)
Time Frame: 14 days (each period)
|
Measured via Blinded Continuous Glucose Monitoring (CGM).
We will collect CGM data over the course of the study during each of the three, 14-day periods as the primary clinical measure.
This is an apt measure that is meaningful and interpretable across the spectrum of glycemic/metabolic abnormality to frank type 2 diabetes.
The inherent major influence of CV is postprandial glucose, which is meaningful across the same spectrum for disease risk.
We will use the Abbott Freestyle Libre Pro system.
|
14 days (each period)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CGM Time in Range
Time Frame: 14 days (each period)
|
the amount of time spent in the target blood glucose (blood sugar) range-between 70 and 180 mg/dL
|
14 days (each period)
|
|
CGM Mean glucose
Time Frame: 14 days (each period)
|
Mean glucose (mg/dL)
|
14 days (each period)
|
|
Blood pressure
Time Frame: End of each 14-day period
|
Systolic and Diastolic blood pressure, standard clinical measurement
|
End of each 14-day period
|
|
Dietary Quality
Time Frame: Each 14-day period
|
HEI dietary quality score as derived from 3 unannounced 24-hour dietary recalls each period (1 weekend, 2 non-consecutive weekdays), scored 0-100, higher = better diet quality
|
Each 14-day period
|
|
Weight (kg)
Time Frame: End of each 14-day period
|
Weight measured on standardized scale
|
End of each 14-day period
|
|
Physical activity
Time Frame: 7-days Each period
|
Mean MET/hour objective measured via Activpal
|
7-days Each period
|
|
Sleep
Time Frame: 7-days Each period
|
Mean hours/day Objectively measured via Activpal
|
7-days Each period
|
|
Food preference and food reward
Time Frame: End of each 14-day period
|
Leeds Food Preference Questionnaire
|
End of each 14-day period
|
|
Quality of life and well-being (Short-Form 12, SF-12)
Time Frame: End of each 14-day period
|
SF-12 The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life.
It is often used as a quality of life measure.
with a range from 0 to 100, with higher scores representing better self-reported health
|
End of each 14-day period
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1477
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Pressure
-
GE HealthcareCompleted
-
Taiwan Biophotonic CorporationCompletedBlood Pressure | Blood Pressure VariabilityTaiwan
-
Université de SherbrookeRecruitingBlood Pressure | Blood Pressure Monitoring, Ambulatory | Blood Pressure, High | Blood Pressure ManagementCanada
-
ROX Medical, Inc.CompletedHypertension | Blood Pressure, High | Blood Pressure, Resistant | Blood Pressure, UncontrolledUnited Kingdom, Netherlands, Belgium
-
DongGuk UniversityActive, not recruitingHypertension | Blood Pressure | Ambulatory Blood Pressure | Home Blood Pressure MeasurementKorea, Republic of
-
Sky LabsSamsung Medical CenterRecruitingHypertension | Blood Pressure | Hypotension | Blood Pressure, High | Blood Pressure, LowKorea, Republic of
-
SE HealthCentre for Aging and Brain Health InnovationCompletedHypertension | Blood Pressure | Hypotension | High Blood Pressure | Low Blood PressureCanada
-
University of JordanCompletedBlood Pressure | Heart Rate | Airway PressureJordan
-
Centre Hospitalier Universitaire VaudoisRecruitingBlood Pressure | Blood Pressure DisordersSwitzerland
-
Istituto Auxologico ItalianoCompletedArterial Hypertension | Ambulatory Blood Pressure Monitoring | Blood Pressure Determination | Home Blood Pressure MonitoringItaly
Clinical Trials on Regular sweetened commercial foods
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingCognitive Impairment | Cognitive Decline | Genetic Risk Factors | Diet Interventions | Obesity &Amp; OverweightChina
-
Sun Yat-sen UniversityLanZhou UniversityEnrolling by invitation
-
Clinical Nutrition Research Centre, SingaporeRecruitingNutrition, HealthySingapore
-
Fundació Sant Joan de DéuActive, not recruitingInfant Growth | Childhood OverweightSpain
-
University of MichiganRecruitingSystemic Sclerosis (SSc)United States
-
Laval UniversityActive, not recruitingMetabolic Syndrome | Gut MicrobiotaCanada